Global Gene Editing Market

Gene Editing Comprehensive Study by Type (Clustered Regularly Interspaced Short Palindromic Repeats, Transcription Activator-like Effector Nucleases (TALEN), Zinc-finger Nucleases (ZFNs), Homing Endonucleases or Meganucleases), Application (Biotechnology Industry, Horticulture Industry, Animal Breeding, Academic and Research Institutes), End Users (Biotech and Pharma Companies, Contract Research Organization (CRO), Research Institutes), Technology (CRISPR/Cas9, Zinc Finger Nucleases (ZFNs), TALENS) Players and Region - Global Market Outlook to 2026

Gene Editing Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 14.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Gene Editing Market Scope
Gene editing refers to the specific changes to be made in human genome. Of late, there has been significant rise in genetic research and in which Cas9–sgRNA has played crucial role. Owing to its ease in use, it has become vital component across the laboratories in the globe. Rising investments in emerging countries coupled with government support is expected to propel the market during forecasted period.

According to AMA, the Global Gene Editing market is expected to see growth rate of 14.8% and may see market size of USD7.83 Billion by 2026.

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Gene Editing market throughout the predicted period.

RGen Solutions (United States), New England Biolabs Inc (United States), GeneCopoeia, Inc. (United States), Genscript Biotech Corporation (United States), OriGene Technologies, Inc. (United States), Agilent Technologies (United States) and Lonza Group (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Addgene (United States), Allele Biotech (United States), Bio-Rad (United States), Takara Bio (Japan), CRISPR Therapeutics (Switzerland), Edits Medicine (United States), Intellia Therapeutics (United States) and Integrated DNA Technologies (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Gene Editing market by Type (Clustered Regularly Interspaced Short Palindromic Repeats, Transcription Activator-like Effector Nucleases (TALEN), Zinc-finger Nucleases (ZFNs) and Homing Endonucleases or Meganucleases), by Application (Biotechnology Industry, Horticulture Industry, Animal Breeding and Academic and Research Institutes) and Region with country level break-up.

On the basis of geography, the market of Gene Editing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Growing Use of Fluorophore Tags, Cas9-fusion Proteins and Cas9 Alternatives
  • High Adoption of CRISPR Based Technology

Market Drivers
  • Growing Prevalence of Chronic Diseases and Cancer
  • Rising Expenditure in Research and Development Activities

Opportunities
  • Growing Developments in Asia Pacific Owing to Increasing Investment
  • Rise in Drug Discovery and Development Activities

Restraints
  • Stringent Regulatory Guidelines for Gene Editing
  • High Cost Involved in Developments of Gene Editing

Challenges
  • Lack of Expertise for Gene Editing Development
  • Complexity Involved in Development Processes


Key Target Audience
Pharmaceutical Companies, Raw Materials Suppliers/Distributors, Potential Investors, Market and Research Firms, Government Agencies, Industry Associations and Others

Report Objectives / Segmentation Covered

By Type
  • Clustered Regularly Interspaced Short Palindromic Repeats
  • Transcription Activator-like Effector Nucleases (TALEN)
  • Zinc-finger Nucleases (ZFNs)
  • Homing Endonucleases or Meganucleases
By Application
  • Biotechnology Industry
  • Horticulture Industry
  • Animal Breeding
  • Academic and Research Institutes
By End Users
  • Biotech and Pharma Companies
  • Contract Research Organization (CRO)
  • Research Institutes

By Technology
  • CRISPR/Cas9
  • Zinc Finger Nucleases (ZFNs)
  • TALENS

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Chronic Diseases and Cancer
      • 3.2.2. Rising Expenditure in Research and Development Activities
    • 3.3. Market Challenges
      • 3.3.1. Lack of Expertise for Gene Editing Development
      • 3.3.2. Complexity Involved in Development Processes
    • 3.4. Market Trends
      • 3.4.1. Growing Use of Fluorophore Tags, Cas9-fusion Proteins and Cas9 Alternatives
      • 3.4.2. High Adoption of CRISPR Based Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gene Editing, by Type, Application, End Users, Technology and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Gene Editing (Value)
      • 5.2.1. Global Gene Editing by: Type (Value)
        • 5.2.1.1. Clustered Regularly Interspaced Short Palindromic Repeats
        • 5.2.1.2. Transcription Activator-like Effector Nucleases (TALEN)
        • 5.2.1.3. Zinc-finger Nucleases (ZFNs)
        • 5.2.1.4. Homing Endonucleases or Meganucleases
      • 5.2.2. Global Gene Editing by: Application (Value)
        • 5.2.2.1. Biotechnology Industry
        • 5.2.2.2. Horticulture Industry
        • 5.2.2.3. Animal Breeding
        • 5.2.2.4. Academic and Research Institutes
      • 5.2.3. Global Gene Editing by: End Users (Value)
        • 5.2.3.1. Biotech and Pharma Companies
        • 5.2.3.2. Contract Research Organization (CRO)
        • 5.2.3.3. Research Institutes
      • 5.2.4. Global Gene Editing by: Technology (Value)
        • 5.2.4.1. CRISPR/Cas9
        • 5.2.4.2. Zinc Finger Nucleases (ZFNs)
        • 5.2.4.3. TALENS
      • 5.2.5. Global Gene Editing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Gene Editing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. RGen Solutions (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. New England Biolabs Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GeneCopoeia, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Genscript Biotech Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. OriGene Technologies, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Agilent Technologies (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lonza Group (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Gene Editing Sale, by Type, Application, End Users, Technology and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Gene Editing (Value)
      • 7.2.1. Global Gene Editing by: Type (Value)
        • 7.2.1.1. Clustered Regularly Interspaced Short Palindromic Repeats
        • 7.2.1.2. Transcription Activator-like Effector Nucleases (TALEN)
        • 7.2.1.3. Zinc-finger Nucleases (ZFNs)
        • 7.2.1.4. Homing Endonucleases or Meganucleases
      • 7.2.2. Global Gene Editing by: Application (Value)
        • 7.2.2.1. Biotechnology Industry
        • 7.2.2.2. Horticulture Industry
        • 7.2.2.3. Animal Breeding
        • 7.2.2.4. Academic and Research Institutes
      • 7.2.3. Global Gene Editing by: End Users (Value)
        • 7.2.3.1. Biotech and Pharma Companies
        • 7.2.3.2. Contract Research Organization (CRO)
        • 7.2.3.3. Research Institutes
      • 7.2.4. Global Gene Editing by: Technology (Value)
        • 7.2.4.1. CRISPR/Cas9
        • 7.2.4.2. Zinc Finger Nucleases (ZFNs)
        • 7.2.4.3. TALENS
      • 7.2.5. Global Gene Editing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gene Editing: by Type(USD Billion)
  • Table 2. Gene Editing Clustered Regularly Interspaced Short Palindromic Repeats , by Region USD Billion (2015-2020)
  • Table 3. Gene Editing Transcription Activator-like Effector Nucleases (TALEN) , by Region USD Billion (2015-2020)
  • Table 4. Gene Editing Zinc-finger Nucleases (ZFNs) , by Region USD Billion (2015-2020)
  • Table 5. Gene Editing Homing Endonucleases or Meganucleases , by Region USD Billion (2015-2020)
  • Table 6. Gene Editing: by Application(USD Billion)
  • Table 7. Gene Editing Biotechnology Industry , by Region USD Billion (2015-2020)
  • Table 8. Gene Editing Horticulture Industry , by Region USD Billion (2015-2020)
  • Table 9. Gene Editing Animal Breeding , by Region USD Billion (2015-2020)
  • Table 10. Gene Editing Academic and Research Institutes , by Region USD Billion (2015-2020)
  • Table 11. Gene Editing: by End Users(USD Billion)
  • Table 12. Gene Editing Biotech and Pharma Companies , by Region USD Billion (2015-2020)
  • Table 13. Gene Editing Contract Research Organization (CRO) , by Region USD Billion (2015-2020)
  • Table 14. Gene Editing Research Institutes , by Region USD Billion (2015-2020)
  • Table 15. Gene Editing: by Technology(USD Billion)
  • Table 16. Gene Editing CRISPR/Cas9 , by Region USD Billion (2015-2020)
  • Table 17. Gene Editing Zinc Finger Nucleases (ZFNs) , by Region USD Billion (2015-2020)
  • Table 18. Gene Editing TALENS , by Region USD Billion (2015-2020)
  • Table 19. South America Gene Editing, by Country USD Billion (2015-2020)
  • Table 20. South America Gene Editing, by Type USD Billion (2015-2020)
  • Table 21. South America Gene Editing, by Application USD Billion (2015-2020)
  • Table 22. South America Gene Editing, by End Users USD Billion (2015-2020)
  • Table 23. South America Gene Editing, by Technology USD Billion (2015-2020)
  • Table 24. Brazil Gene Editing, by Type USD Billion (2015-2020)
  • Table 25. Brazil Gene Editing, by Application USD Billion (2015-2020)
  • Table 26. Brazil Gene Editing, by End Users USD Billion (2015-2020)
  • Table 27. Brazil Gene Editing, by Technology USD Billion (2015-2020)
  • Table 28. Argentina Gene Editing, by Type USD Billion (2015-2020)
  • Table 29. Argentina Gene Editing, by Application USD Billion (2015-2020)
  • Table 30. Argentina Gene Editing, by End Users USD Billion (2015-2020)
  • Table 31. Argentina Gene Editing, by Technology USD Billion (2015-2020)
  • Table 32. Rest of South America Gene Editing, by Type USD Billion (2015-2020)
  • Table 33. Rest of South America Gene Editing, by Application USD Billion (2015-2020)
  • Table 34. Rest of South America Gene Editing, by End Users USD Billion (2015-2020)
  • Table 35. Rest of South America Gene Editing, by Technology USD Billion (2015-2020)
  • Table 36. Asia Pacific Gene Editing, by Country USD Billion (2015-2020)
  • Table 37. Asia Pacific Gene Editing, by Type USD Billion (2015-2020)
  • Table 38. Asia Pacific Gene Editing, by Application USD Billion (2015-2020)
  • Table 39. Asia Pacific Gene Editing, by End Users USD Billion (2015-2020)
  • Table 40. Asia Pacific Gene Editing, by Technology USD Billion (2015-2020)
  • Table 41. China Gene Editing, by Type USD Billion (2015-2020)
  • Table 42. China Gene Editing, by Application USD Billion (2015-2020)
  • Table 43. China Gene Editing, by End Users USD Billion (2015-2020)
  • Table 44. China Gene Editing, by Technology USD Billion (2015-2020)
  • Table 45. Japan Gene Editing, by Type USD Billion (2015-2020)
  • Table 46. Japan Gene Editing, by Application USD Billion (2015-2020)
  • Table 47. Japan Gene Editing, by End Users USD Billion (2015-2020)
  • Table 48. Japan Gene Editing, by Technology USD Billion (2015-2020)
  • Table 49. India Gene Editing, by Type USD Billion (2015-2020)
  • Table 50. India Gene Editing, by Application USD Billion (2015-2020)
  • Table 51. India Gene Editing, by End Users USD Billion (2015-2020)
  • Table 52. India Gene Editing, by Technology USD Billion (2015-2020)
  • Table 53. South Korea Gene Editing, by Type USD Billion (2015-2020)
  • Table 54. South Korea Gene Editing, by Application USD Billion (2015-2020)
  • Table 55. South Korea Gene Editing, by End Users USD Billion (2015-2020)
  • Table 56. South Korea Gene Editing, by Technology USD Billion (2015-2020)
  • Table 57. Taiwan Gene Editing, by Type USD Billion (2015-2020)
  • Table 58. Taiwan Gene Editing, by Application USD Billion (2015-2020)
  • Table 59. Taiwan Gene Editing, by End Users USD Billion (2015-2020)
  • Table 60. Taiwan Gene Editing, by Technology USD Billion (2015-2020)
  • Table 61. Australia Gene Editing, by Type USD Billion (2015-2020)
  • Table 62. Australia Gene Editing, by Application USD Billion (2015-2020)
  • Table 63. Australia Gene Editing, by End Users USD Billion (2015-2020)
  • Table 64. Australia Gene Editing, by Technology USD Billion (2015-2020)
  • Table 65. Rest of Asia-Pacific Gene Editing, by Type USD Billion (2015-2020)
  • Table 66. Rest of Asia-Pacific Gene Editing, by Application USD Billion (2015-2020)
  • Table 67. Rest of Asia-Pacific Gene Editing, by End Users USD Billion (2015-2020)
  • Table 68. Rest of Asia-Pacific Gene Editing, by Technology USD Billion (2015-2020)
  • Table 69. Europe Gene Editing, by Country USD Billion (2015-2020)
  • Table 70. Europe Gene Editing, by Type USD Billion (2015-2020)
  • Table 71. Europe Gene Editing, by Application USD Billion (2015-2020)
  • Table 72. Europe Gene Editing, by End Users USD Billion (2015-2020)
  • Table 73. Europe Gene Editing, by Technology USD Billion (2015-2020)
  • Table 74. Germany Gene Editing, by Type USD Billion (2015-2020)
  • Table 75. Germany Gene Editing, by Application USD Billion (2015-2020)
  • Table 76. Germany Gene Editing, by End Users USD Billion (2015-2020)
  • Table 77. Germany Gene Editing, by Technology USD Billion (2015-2020)
  • Table 78. France Gene Editing, by Type USD Billion (2015-2020)
  • Table 79. France Gene Editing, by Application USD Billion (2015-2020)
  • Table 80. France Gene Editing, by End Users USD Billion (2015-2020)
  • Table 81. France Gene Editing, by Technology USD Billion (2015-2020)
  • Table 82. Italy Gene Editing, by Type USD Billion (2015-2020)
  • Table 83. Italy Gene Editing, by Application USD Billion (2015-2020)
  • Table 84. Italy Gene Editing, by End Users USD Billion (2015-2020)
  • Table 85. Italy Gene Editing, by Technology USD Billion (2015-2020)
  • Table 86. United Kingdom Gene Editing, by Type USD Billion (2015-2020)
  • Table 87. United Kingdom Gene Editing, by Application USD Billion (2015-2020)
  • Table 88. United Kingdom Gene Editing, by End Users USD Billion (2015-2020)
  • Table 89. United Kingdom Gene Editing, by Technology USD Billion (2015-2020)
  • Table 90. Netherlands Gene Editing, by Type USD Billion (2015-2020)
  • Table 91. Netherlands Gene Editing, by Application USD Billion (2015-2020)
  • Table 92. Netherlands Gene Editing, by End Users USD Billion (2015-2020)
  • Table 93. Netherlands Gene Editing, by Technology USD Billion (2015-2020)
  • Table 94. Rest of Europe Gene Editing, by Type USD Billion (2015-2020)
  • Table 95. Rest of Europe Gene Editing, by Application USD Billion (2015-2020)
  • Table 96. Rest of Europe Gene Editing, by End Users USD Billion (2015-2020)
  • Table 97. Rest of Europe Gene Editing, by Technology USD Billion (2015-2020)
  • Table 98. MEA Gene Editing, by Country USD Billion (2015-2020)
  • Table 99. MEA Gene Editing, by Type USD Billion (2015-2020)
  • Table 100. MEA Gene Editing, by Application USD Billion (2015-2020)
  • Table 101. MEA Gene Editing, by End Users USD Billion (2015-2020)
  • Table 102. MEA Gene Editing, by Technology USD Billion (2015-2020)
  • Table 103. Middle East Gene Editing, by Type USD Billion (2015-2020)
  • Table 104. Middle East Gene Editing, by Application USD Billion (2015-2020)
  • Table 105. Middle East Gene Editing, by End Users USD Billion (2015-2020)
  • Table 106. Middle East Gene Editing, by Technology USD Billion (2015-2020)
  • Table 107. Africa Gene Editing, by Type USD Billion (2015-2020)
  • Table 108. Africa Gene Editing, by Application USD Billion (2015-2020)
  • Table 109. Africa Gene Editing, by End Users USD Billion (2015-2020)
  • Table 110. Africa Gene Editing, by Technology USD Billion (2015-2020)
  • Table 111. North America Gene Editing, by Country USD Billion (2015-2020)
  • Table 112. North America Gene Editing, by Type USD Billion (2015-2020)
  • Table 113. North America Gene Editing, by Application USD Billion (2015-2020)
  • Table 114. North America Gene Editing, by End Users USD Billion (2015-2020)
  • Table 115. North America Gene Editing, by Technology USD Billion (2015-2020)
  • Table 116. United States Gene Editing, by Type USD Billion (2015-2020)
  • Table 117. United States Gene Editing, by Application USD Billion (2015-2020)
  • Table 118. United States Gene Editing, by End Users USD Billion (2015-2020)
  • Table 119. United States Gene Editing, by Technology USD Billion (2015-2020)
  • Table 120. Canada Gene Editing, by Type USD Billion (2015-2020)
  • Table 121. Canada Gene Editing, by Application USD Billion (2015-2020)
  • Table 122. Canada Gene Editing, by End Users USD Billion (2015-2020)
  • Table 123. Canada Gene Editing, by Technology USD Billion (2015-2020)
  • Table 124. Mexico Gene Editing, by Type USD Billion (2015-2020)
  • Table 125. Mexico Gene Editing, by Application USD Billion (2015-2020)
  • Table 126. Mexico Gene Editing, by End Users USD Billion (2015-2020)
  • Table 127. Mexico Gene Editing, by Technology USD Billion (2015-2020)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Gene Editing: by Type(USD Billion)
  • Table 136. Gene Editing Clustered Regularly Interspaced Short Palindromic Repeats , by Region USD Billion (2021-2026)
  • Table 137. Gene Editing Transcription Activator-like Effector Nucleases (TALEN) , by Region USD Billion (2021-2026)
  • Table 138. Gene Editing Zinc-finger Nucleases (ZFNs) , by Region USD Billion (2021-2026)
  • Table 139. Gene Editing Homing Endonucleases or Meganucleases , by Region USD Billion (2021-2026)
  • Table 140. Gene Editing: by Application(USD Billion)
  • Table 141. Gene Editing Biotechnology Industry , by Region USD Billion (2021-2026)
  • Table 142. Gene Editing Horticulture Industry , by Region USD Billion (2021-2026)
  • Table 143. Gene Editing Animal Breeding , by Region USD Billion (2021-2026)
  • Table 144. Gene Editing Academic and Research Institutes , by Region USD Billion (2021-2026)
  • Table 145. Gene Editing: by End Users(USD Billion)
  • Table 146. Gene Editing Biotech and Pharma Companies , by Region USD Billion (2021-2026)
  • Table 147. Gene Editing Contract Research Organization (CRO) , by Region USD Billion (2021-2026)
  • Table 148. Gene Editing Research Institutes , by Region USD Billion (2021-2026)
  • Table 149. Gene Editing: by Technology(USD Billion)
  • Table 150. Gene Editing CRISPR/Cas9 , by Region USD Billion (2021-2026)
  • Table 151. Gene Editing Zinc Finger Nucleases (ZFNs) , by Region USD Billion (2021-2026)
  • Table 152. Gene Editing TALENS , by Region USD Billion (2021-2026)
  • Table 153. South America Gene Editing, by Country USD Billion (2021-2026)
  • Table 154. South America Gene Editing, by Type USD Billion (2021-2026)
  • Table 155. South America Gene Editing, by Application USD Billion (2021-2026)
  • Table 156. South America Gene Editing, by End Users USD Billion (2021-2026)
  • Table 157. South America Gene Editing, by Technology USD Billion (2021-2026)
  • Table 158. Brazil Gene Editing, by Type USD Billion (2021-2026)
  • Table 159. Brazil Gene Editing, by Application USD Billion (2021-2026)
  • Table 160. Brazil Gene Editing, by End Users USD Billion (2021-2026)
  • Table 161. Brazil Gene Editing, by Technology USD Billion (2021-2026)
  • Table 162. Argentina Gene Editing, by Type USD Billion (2021-2026)
  • Table 163. Argentina Gene Editing, by Application USD Billion (2021-2026)
  • Table 164. Argentina Gene Editing, by End Users USD Billion (2021-2026)
  • Table 165. Argentina Gene Editing, by Technology USD Billion (2021-2026)
  • Table 166. Rest of South America Gene Editing, by Type USD Billion (2021-2026)
  • Table 167. Rest of South America Gene Editing, by Application USD Billion (2021-2026)
  • Table 168. Rest of South America Gene Editing, by End Users USD Billion (2021-2026)
  • Table 169. Rest of South America Gene Editing, by Technology USD Billion (2021-2026)
  • Table 170. Asia Pacific Gene Editing, by Country USD Billion (2021-2026)
  • Table 171. Asia Pacific Gene Editing, by Type USD Billion (2021-2026)
  • Table 172. Asia Pacific Gene Editing, by Application USD Billion (2021-2026)
  • Table 173. Asia Pacific Gene Editing, by End Users USD Billion (2021-2026)
  • Table 174. Asia Pacific Gene Editing, by Technology USD Billion (2021-2026)
  • Table 175. China Gene Editing, by Type USD Billion (2021-2026)
  • Table 176. China Gene Editing, by Application USD Billion (2021-2026)
  • Table 177. China Gene Editing, by End Users USD Billion (2021-2026)
  • Table 178. China Gene Editing, by Technology USD Billion (2021-2026)
  • Table 179. Japan Gene Editing, by Type USD Billion (2021-2026)
  • Table 180. Japan Gene Editing, by Application USD Billion (2021-2026)
  • Table 181. Japan Gene Editing, by End Users USD Billion (2021-2026)
  • Table 182. Japan Gene Editing, by Technology USD Billion (2021-2026)
  • Table 183. India Gene Editing, by Type USD Billion (2021-2026)
  • Table 184. India Gene Editing, by Application USD Billion (2021-2026)
  • Table 185. India Gene Editing, by End Users USD Billion (2021-2026)
  • Table 186. India Gene Editing, by Technology USD Billion (2021-2026)
  • Table 187. South Korea Gene Editing, by Type USD Billion (2021-2026)
  • Table 188. South Korea Gene Editing, by Application USD Billion (2021-2026)
  • Table 189. South Korea Gene Editing, by End Users USD Billion (2021-2026)
  • Table 190. South Korea Gene Editing, by Technology USD Billion (2021-2026)
  • Table 191. Taiwan Gene Editing, by Type USD Billion (2021-2026)
  • Table 192. Taiwan Gene Editing, by Application USD Billion (2021-2026)
  • Table 193. Taiwan Gene Editing, by End Users USD Billion (2021-2026)
  • Table 194. Taiwan Gene Editing, by Technology USD Billion (2021-2026)
  • Table 195. Australia Gene Editing, by Type USD Billion (2021-2026)
  • Table 196. Australia Gene Editing, by Application USD Billion (2021-2026)
  • Table 197. Australia Gene Editing, by End Users USD Billion (2021-2026)
  • Table 198. Australia Gene Editing, by Technology USD Billion (2021-2026)
  • Table 199. Rest of Asia-Pacific Gene Editing, by Type USD Billion (2021-2026)
  • Table 200. Rest of Asia-Pacific Gene Editing, by Application USD Billion (2021-2026)
  • Table 201. Rest of Asia-Pacific Gene Editing, by End Users USD Billion (2021-2026)
  • Table 202. Rest of Asia-Pacific Gene Editing, by Technology USD Billion (2021-2026)
  • Table 203. Europe Gene Editing, by Country USD Billion (2021-2026)
  • Table 204. Europe Gene Editing, by Type USD Billion (2021-2026)
  • Table 205. Europe Gene Editing, by Application USD Billion (2021-2026)
  • Table 206. Europe Gene Editing, by End Users USD Billion (2021-2026)
  • Table 207. Europe Gene Editing, by Technology USD Billion (2021-2026)
  • Table 208. Germany Gene Editing, by Type USD Billion (2021-2026)
  • Table 209. Germany Gene Editing, by Application USD Billion (2021-2026)
  • Table 210. Germany Gene Editing, by End Users USD Billion (2021-2026)
  • Table 211. Germany Gene Editing, by Technology USD Billion (2021-2026)
  • Table 212. France Gene Editing, by Type USD Billion (2021-2026)
  • Table 213. France Gene Editing, by Application USD Billion (2021-2026)
  • Table 214. France Gene Editing, by End Users USD Billion (2021-2026)
  • Table 215. France Gene Editing, by Technology USD Billion (2021-2026)
  • Table 216. Italy Gene Editing, by Type USD Billion (2021-2026)
  • Table 217. Italy Gene Editing, by Application USD Billion (2021-2026)
  • Table 218. Italy Gene Editing, by End Users USD Billion (2021-2026)
  • Table 219. Italy Gene Editing, by Technology USD Billion (2021-2026)
  • Table 220. United Kingdom Gene Editing, by Type USD Billion (2021-2026)
  • Table 221. United Kingdom Gene Editing, by Application USD Billion (2021-2026)
  • Table 222. United Kingdom Gene Editing, by End Users USD Billion (2021-2026)
  • Table 223. United Kingdom Gene Editing, by Technology USD Billion (2021-2026)
  • Table 224. Netherlands Gene Editing, by Type USD Billion (2021-2026)
  • Table 225. Netherlands Gene Editing, by Application USD Billion (2021-2026)
  • Table 226. Netherlands Gene Editing, by End Users USD Billion (2021-2026)
  • Table 227. Netherlands Gene Editing, by Technology USD Billion (2021-2026)
  • Table 228. Rest of Europe Gene Editing, by Type USD Billion (2021-2026)
  • Table 229. Rest of Europe Gene Editing, by Application USD Billion (2021-2026)
  • Table 230. Rest of Europe Gene Editing, by End Users USD Billion (2021-2026)
  • Table 231. Rest of Europe Gene Editing, by Technology USD Billion (2021-2026)
  • Table 232. MEA Gene Editing, by Country USD Billion (2021-2026)
  • Table 233. MEA Gene Editing, by Type USD Billion (2021-2026)
  • Table 234. MEA Gene Editing, by Application USD Billion (2021-2026)
  • Table 235. MEA Gene Editing, by End Users USD Billion (2021-2026)
  • Table 236. MEA Gene Editing, by Technology USD Billion (2021-2026)
  • Table 237. Middle East Gene Editing, by Type USD Billion (2021-2026)
  • Table 238. Middle East Gene Editing, by Application USD Billion (2021-2026)
  • Table 239. Middle East Gene Editing, by End Users USD Billion (2021-2026)
  • Table 240. Middle East Gene Editing, by Technology USD Billion (2021-2026)
  • Table 241. Africa Gene Editing, by Type USD Billion (2021-2026)
  • Table 242. Africa Gene Editing, by Application USD Billion (2021-2026)
  • Table 243. Africa Gene Editing, by End Users USD Billion (2021-2026)
  • Table 244. Africa Gene Editing, by Technology USD Billion (2021-2026)
  • Table 245. North America Gene Editing, by Country USD Billion (2021-2026)
  • Table 246. North America Gene Editing, by Type USD Billion (2021-2026)
  • Table 247. North America Gene Editing, by Application USD Billion (2021-2026)
  • Table 248. North America Gene Editing, by End Users USD Billion (2021-2026)
  • Table 249. North America Gene Editing, by Technology USD Billion (2021-2026)
  • Table 250. United States Gene Editing, by Type USD Billion (2021-2026)
  • Table 251. United States Gene Editing, by Application USD Billion (2021-2026)
  • Table 252. United States Gene Editing, by End Users USD Billion (2021-2026)
  • Table 253. United States Gene Editing, by Technology USD Billion (2021-2026)
  • Table 254. Canada Gene Editing, by Type USD Billion (2021-2026)
  • Table 255. Canada Gene Editing, by Application USD Billion (2021-2026)
  • Table 256. Canada Gene Editing, by End Users USD Billion (2021-2026)
  • Table 257. Canada Gene Editing, by Technology USD Billion (2021-2026)
  • Table 258. Mexico Gene Editing, by Type USD Billion (2021-2026)
  • Table 259. Mexico Gene Editing, by Application USD Billion (2021-2026)
  • Table 260. Mexico Gene Editing, by End Users USD Billion (2021-2026)
  • Table 261. Mexico Gene Editing, by Technology USD Billion (2021-2026)
  • Table 262. Research Programs/Design for This Report
  • Table 263. Key Data Information from Secondary Sources
  • Table 264. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gene Editing: by Type USD Billion (2015-2020)
  • Figure 5. Global Gene Editing: by Application USD Billion (2015-2020)
  • Figure 6. Global Gene Editing: by End Users USD Billion (2015-2020)
  • Figure 7. Global Gene Editing: by Technology USD Billion (2015-2020)
  • Figure 8. South America Gene Editing Share (%), by Country
  • Figure 9. Asia Pacific Gene Editing Share (%), by Country
  • Figure 10. Europe Gene Editing Share (%), by Country
  • Figure 11. MEA Gene Editing Share (%), by Country
  • Figure 12. North America Gene Editing Share (%), by Country
  • Figure 13. Global Gene Editing share by Players 2020 (%)
  • Figure 14. Global Gene Editing share by Players (Top 3) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. RGen Solutions (United States) Revenue, Net Income and Gross profit
  • Figure 17. RGen Solutions (United States) Revenue: by Geography 2020
  • Figure 18. New England Biolabs Inc (United States) Revenue, Net Income and Gross profit
  • Figure 19. New England Biolabs Inc (United States) Revenue: by Geography 2020
  • Figure 20. GeneCopoeia, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. GeneCopoeia, Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Genscript Biotech Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 23. Genscript Biotech Corporation (United States) Revenue: by Geography 2020
  • Figure 24. OriGene Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. OriGene Technologies, Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 27. Agilent Technologies (United States) Revenue: by Geography 2020
  • Figure 28. Lonza Group (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Lonza Group (Switzerland) Revenue: by Geography 2020
  • Figure 30. Global Gene Editing: by Type USD Billion (2021-2026)
  • Figure 31. Global Gene Editing: by Application USD Billion (2021-2026)
  • Figure 32. Global Gene Editing: by End Users USD Billion (2021-2026)
  • Figure 33. Global Gene Editing: by Technology USD Billion (2021-2026)
  • Figure 34. South America Gene Editing Share (%), by Country
  • Figure 35. Asia Pacific Gene Editing Share (%), by Country
  • Figure 36. Europe Gene Editing Share (%), by Country
  • Figure 37. MEA Gene Editing Share (%), by Country
  • Figure 38. North America Gene Editing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • RGen Solutions (United States)
  • New England Biolabs Inc (United States)
  • GeneCopoeia, Inc. (United States)
  • Genscript Biotech Corporation (United States)
  • OriGene Technologies, Inc. (United States)
  • Agilent Technologies (United States)
  • Lonza Group (Switzerland)
Additional players considered in the study are as follows:
Addgene (United States) , Allele Biotech (United States) , Bio-Rad (United States) , Takara Bio (Japan) , CRISPR Therapeutics (Switzerland) , Edits Medicine (United States) , Intellia Therapeutics (United States) , Integrated DNA Technologies (United States)
Select User Access Type

Key Highlights of Report


Sep 2021 240 Pages 93 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gene Editing Market Quantitative research analysis
Global Gene Editing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Gene Editing study can be customized to meet your requirements. The market size breakdown by type [Clustered Regularly Interspaced Short Palindromic Repeats, Transcription Activator-like Effector Nucleases (TALEN), Zinc-finger Nucleases (ZFNs) and Homing Endonucleases or Meganucleases], by end use application [Biotechnology Industry, Horticulture Industry, Animal Breeding and Academic and Research Institutes].
The Gene Editing Market is gaining popularity and expected to see strong valuation by 2026.
According to AMA, the Global Gene Editing market is expected to see growth rate of 14.8%.

Know More About Global Gene Editing Market Report?

Have a Query? Click Here

Other Related Reports

Sulfasalazine Tablets Comprehensive Study by Type (Enteric Sugar Coated Tablet, Film-Coated Tablet, Other), Application (Fever, Arthritis, Stomach pain, Diarrhea, Rectal bleeding, Others), Shape (Ova...
$ 3350
Biopharmaceutical Comprehensive Study by Type (Monoclonal Antibodies, Erythropoietin (EPO), Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferon...
$ 3750
Human Albumin Comprehensive Study by Type (Human Serum Albumin, Recombinant Serum Albumin), Application (Drug Delivery, Therapeutics, Culture Media, Vaccine Ingredient, Others), End-User (Pharmaceuti...
$ 3450
Pyrolysis Gasoline Comprehensive Study by Type (Raw Pyrolysis Gasoline, Hydrogenated Pyrolysis Gasoline), Application (Aromatics Extraction, Refinery Feedstock, Fractionation for Benzene, Others), En...
$ 3450
Pharmaceutical Gelatin Comprehensive Study by Application (Hard Capsules, Soft Capsules, Micro-encapsulation, Coating for Tablets, Absorbable Hemostat), Function (Stabilizers, Thickeners, Gelling Age...
$ 3450
Sunitinib Malate Comprehensive Study by Application (Kidney Cancer, Pancreas Cancer, Intestinal Cancer), Distribution Channel (Hospital Pharmacy, Retail Drug Stores), Dosage (12.5mg, 25mg, 37.5mg, 50...
$ 3650